Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Physiological Regulating Medicine in Pediatric Chronic Atopic Dermatitis
2010-018640-13Phase 4Completed
- Sponsor
- GUNA S.P.A.
- Start
- Jan 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of interferon gamma-1b and recombinant interleukin-12 in atopic dermatitis (AD) (2 arms), sponsored by GUNA S.P.A. Primary endpoint: Reduction in severity of atopic dermatitis. Started Jan 2021; status: completed.
02
Drugs
interferon gamma-1brecombinant interleukin-12
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2010-018640-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018640-13.